real-time news and commentary for investors
Wednesday, Sep 4
Endo Pharmaceuticals, BioDelivery Sciences give BEMA Buprenorphine update
- Endo Pharmaceuticals (ENDP +2.2%) and BioDelivery Sciences (BDSI +0.2%) update investors on the Phase 3 development of BEMA Buprenorphine.
- Interim analyses show no adjustments to the sample size in the opioid naive study will be necessary.
- Patients will be added to the opioid experienced trial.
- ENDP says "no major impact is anticipated for the timing of the NDA submission" but notes that more definitive data regarding timetables will be provided once patient enrollment for the opioid experienced trial is complete. (PR)